Replicative adenoviruses for cancer therapy

Nature Biotechnology

Volumn 18, Issue 7, 2000, Pages 723-727

  Alemany, Ramon ^a   Balagué, Cristina ^a   Curiel, David T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Oncolysis; Replicative adenovirus; Virotherapy

Indexed keywords

ONCOLYTIC VIRUS; VIRUS VECTOR;

ADENOVIRUS; CANCER THERAPY; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC ENGINEERING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

ADENOVIRIDAE; DNA VIRUSES; MIRIDAE;

EID: 0033926002     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/77283     Document Type: Review

References (56)

1. Sinkovics, J. & Horvath, J. New developments in the virus therapy of cancer: a historical review. Intervirology 36, 193-214 (1993).
2. Smith, R.R., Huebner, R.J., Rowe, W.P., Schatten, W.F. & Thomas, L.B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9, 1211-1218 (1956).
3. Coffey, M.C., Strong, J.E., Forsyth, P.A. & Lee, P.W. Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334 (1998).
4. Haag, A. et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum. Gene Ther. 11, 597-609 (2000).
5. Yoon, S.S. et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB. J. 14, 301-311 (2000).
6. Ganly I. et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806 (2000).
7. Lucher, L.A. Abortive adenovirus infection and host range determinants. Curr. Top. Microbiol. Immunol. 199, 119-152 (1995).
8. Hay, J.G. et al. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum. Gene Ther. 10, 579-590 (1999).
9. Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645 (1997).
10. Yu, D.C., Sakamoto, G.T. & Henderson, D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59, 1498-504 (1999).
11. Rothmann, T., Hengstermann, A., Whitaker, N.J., Scheffner, M. & zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72, 9470-9478 (1998).
12. Lu, D. et al. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. Gynecol. Oncol. 75, 84-90 (1999).
13. Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996).
14. Goodrum, F.D. & Ornelles, D.A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479-9490 (1998).
15. Babiss, L.E. & Ginsberg, H.S. Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis. J. Virol. 50, 202-212 (1984).
16. Pilder, S., Moore, M., Logan, J. & Shenk, T. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol. Cell Biol. 6, 470-476 (1986).
17. Harada, J.N. & Berk, A.J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333-5344 (1999).
18. Hall, A.R., Dix, B.R., O'Carroll, S.J. & Braithwaite, A.W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4, 1068-1072 (1998).
19. Wildner, O., Blaese, R.M. & Morris, J.C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59, 410-413 (1999).
20. Rogulski, K.R. et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther 11, 67-76 (2000).
21. Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12 (2000).
22. Wang, H.G., Moran, E. & Yaciuk, P. E1A promotes association between p300 and pRB in multimeric complexes required for normal biological activity. J. Virol. 69, 7917-7924 (1995).
23. Hallenbeck, P.L. et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721-33 (1999).
24. Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563 (1997).
25. Babiss, L.E., Friedman, J.M. & Darnell, J.E., Jr. Cellular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 193, 643-650 (1987).
26. Vassaux, G., Hurst, H.C. & Lemoine, N.R. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. 6, 1192-1197 (1999).
27. Goldsmith, K.T., Curiel, D.T., Engler, J.A. & Carver RI, Jr. Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum. Gene Ther. 5, 1341-1348 (1994).
28. Tollefson, A.E. et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306 (1996).
29. Yu, D.C., Chen, Y., Seng, M., Dilley, J. & Henderson, D.R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200-4203 (1999). (Published erratum appears in Cancer Res. 60, 1150, 2000.)
30. Alemany, R. et al. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6, 21-25 (1999).
31. Motoi, F. et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum. Gene Ther. 11, 223-235 (2000).
32. Duncan, S.J. et al. Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40, 45-61 (1978).
33. Roelvink, P.W., Mi Lee, G., Einfeld, D.A., Kovesdi, I. & Wickham, T.J. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286, 1568-1571 (1999).
34. Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987-992 (1994).
35. Gu, D.L. et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 59 2608-2614 (1999).
36. Curiel, D.T. Strategies to adapt adenoviral vectors for targeted delivery. Ann. NY Acad. Sci. 886, 158-171 (1999).
37. Dmitriev, I. et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713 (1998).
38. Hemmi, S., Geertsen, R., Mezzacasa, A., Peter, I. & Dummer, R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther. 9, 2363-2373 (1998).
39. Li, Y. et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330 (1999).
40. Staba, M.J., Wickham, T.J., Kovesdi, I. & Hallahan, D.E. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7, 13-19 (2000).
41. Shinoura, N. et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59, 3411-3416 (1999).
42. Byrnes, A.P. & Griffin, D.E. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J. Virol. 74, 644-651 (2000).
43. Sauthoft, H., Heitner, S., Rom, W.N. & Hay, J.G. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum. Gene Ther. 11, 379-388 (2000).
44. Duque, P.M. et al. Antitumoral effect of E1B defective adenoviruses in human malignant cells. Gene Ther. 5, 286-287 (1998).
45. Zhang, Y. & Schneider, R.J. Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation of the cytokeratin network. J. Virol. 68, 2544-2555 (1994).
46. Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814s-819s (1990).
47. Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881-887 (1999).
48. Prince, G.A. et al. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J. Virol. 67, 101-111 (1993).
49. Torres, J.M. et al. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J. Virol. 70, 3770-3780 (1996).
50. Oualikene, W., Gonin, P. & Eloit, M. Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton rat) and non-permissive (mouse) species. J. Gen. Virol. 75, 2765-2768 (1994).
51. Khoobyarian, N., Barone, F., Sabet, T., El-Domeiri, A.A. & Das Gupta, T.K. Inhibition of melanoma growth in hamsters by type-2 adenovirus. J. Surg. Oncol. 7, 421-425 (1975).
52. Ganly, I., Mautner, V. & Balmain, A. Productive replication of human adenoviruses in mouse epidermal cells. J. Virol. 74, 2895-2899 (2000).
53. Yang, Y., Trinchieri, G. & Wilson, J.M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1, 890-893 (1995).
54. Zhang, J.F. et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl. Acad. Sci. USA 93, 4513-4518 (1996).
55. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D. & Kim, J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333 (1998).
56. Rancourt, C. et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clin. Cancer Res. 5, 43-50 (1999).